Maze Therapeutics, Inc. 8-K

What Happened
Maze Therapeutics, Inc. filed an 8-K on June 10, 2026 reporting the results of its June 8, 2026 annual meeting of stockholders. Approximately 44,660,029 shares (about 89.75% of outstanding shares entitled to vote) were present virtually or by proxy, constituting a quorum. Stockholders elected Jason Coloma, Ph.D., and Neil Kumar, Ph.D., as Class I directors (terms through the 2029 annual meeting) and ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for 2026.

Key Details

• Meeting date: June 8, 2026; 44,660,029 shares voted (~89.75% turnout).
• Director elections:
  • Jason Coloma, Ph.D.: 35,792,536 votes for; 5,926,467 withheld; 2,941,026 broker non-votes.
  • Neil Kumar, Ph.D.: 34,056,425 votes for; 7,662,578 withheld; 2,941,026 broker non-votes.
• Auditor ratification (Ernst & Young LLP): 44,557,778 votes for; 728 against; 101,523 abstentions; 0 broker non-votes.
• Proxy Statement reference: definitive proxy filed April 28, 2026.

Why It Matters
These results confirm the company’s board composition for the Class I seats through 2029, which affects corporate governance and oversight. Ratification of Ernst & Young LLP secures the company’s independent auditor for 2026, relevant to upcoming financial reporting and audit continuity. The vote totals and ~89.75% participation give investors a clear view of shareholder support levels for governance matters.